Aspirin loaded xerogels for buccal and oral GIT delivery for patients with dysphagia to target deep vein thrombosis by Farias, Smirna
  https://doi.org/10.5920/bjpharm.2017.18  
Farias and Boateng (2017) BJPharm, 2(2), S16-18  S16 
www.bjpharm.hud.ac.uk 
A R T I C L E   I N F O S U M M A R Y 
This study aimed to develop xerogels for delivery of aspirin via the oral (buccal 
mucosa and GIT) route in geriatric patients with dysphagia. Xerogels were prepared 
using low molecular weight chitosan (CS), carrageenan (CAR) and metolose (MET) 
in different ratios, loaded with aspirin (75 mg). Gels (2.5% w/v and 4.0% w/v) were 
prepared (60 °C) using 40% v/v ethanol and freeze dried for 48 hours. Xerogels 
(2.5% w/v MET: CAR 3:1 and 1:1, 4.0% CAR: CS 1:3 and 1:1 and 4.0% MET: CS 1:3 
gels) were characterised with texture analysis (TA) for hardness and mucoadhesion, 
swelling index (%) and porosity (%) to identify an optimised formulation for 
controlled release (buccal) and fast release (GIT) delivery. Scanning electron 
microscopy (SEM) was used to assess surface morphology and X-ray diffraction 
(XRD) to assess the physical form of the formulations (amorphous or crystalline). 
Xerogels from 2.5 % w/v MET: CAR 3:1 and 1:1 gels showed higher swelling 
capacity (%) (more than 2 hours to disintegrate) and can be applied to the buccal 
mucosa for controlled delivery of the API while 4.0 % w/v CAR: CS 1:3 and 1:1 can 
be used as rapid release xerogel (disintegrated within 2 minutes) for oral GIT 
delivery. 
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INTRODUCTION 
Deep vein thrombosis (DVT) results from a blood clot 
or thrombus expanding in the large veins of the legs 
or pelvic area (Vascular Disease Foundation, 2012). 
Demographic ageing, which is expected to cover 30% 
of the EU population by 2050 is likely to be of major 
significance in the coming decades. This will require 
more prescribed medicines due to the presence of new 
diseases and they are also more vulnerable to 
dysphagia due to natural process of aging, which can 
make swallowing of medicines challenging. 
Therefore, alternative solutions specifically tailored to 
the special needs of older populations are required by 
enhancing the development of novel delivery systems 
to improve safety, efficacy and patient compliance 
and increasing the product patent life cycle (Panda, 
2012). Fast dissolving and sustained release 
lyophilised xerogels are examples of innovative 
formulations for buccal mucosa and oral GIT delivery. 
Composite lyophilised xerogels comprised of 
metolose (MET), carrageenan (CAR) and low 
molecular weight chitosan (CS) loaded with 75 mg of 
aspirin have been developed for potential oral (GIT 
and buccal mucosa) delivery. 
MATERIALS AND METHODS 
Different composite xerogels were formulated by 
freeze-drying process. Composite gels were prepared 
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by combining MET with CAR (MET: CAR), MET with 
CS (MET: CS) and CAR with CS (CAR: CS) in different 
weight ratios (Table 1). Functional characterisation 
tests [mechanical hardness, in vitro mucoadhesion, 
swelling capacity (in phosphate buffered saline – PBS, 
and simulated saliva – SS, at pH of 6.8) and porosity 
(%)] were performed in order to select the optimised 
aspirin loaded xerogel for further advanced analytical 
characterization (scanning electron  microscopy 
(SEM), x-ray diffraction (XRD), differential scanning 
calorimetry (DSC)  and  subsequent  selection of 
optimised formulations for eventual oral GIT and 
buccal mucosa delivery. 
RESULTS AND DISCUSSION 
The composite xerogels obtained from 2.5% w/v 
MET: CAR 1:1, 3:1 and 4.0% w/v MET: CS 3:1 and 
4.0% CAR: CS 1:1, 3:1 gels were elegant in appearance 
and non-brittle in nature proving to be suitable for 
potential GIT and buccal mucosa delivery 
respectively. For the formulations composed of 2.5% 
w/v MET: CAR 1:1 and 3:1, the hardness increased 
significantly (p < 0.05), whilst the swelling capacity 
(%) and mucoadhesion decreased with increase in 
MET content (Table 1). Hydration results from Table 
1 showed that % swelling capacity was higher in PBS 
than in SS due to differences in ionic strength of the 
media (Peh, 1999). The hardness results showed that 
xerogels with higher resistance to compression were 
less able to swell due to collapsed pores, while the 
adhesion decreased due to reduced interaction. The 
xerogels comprising 4.0% CAR: CS 1:1 and 3:1 showed 
similar profile as the 2.5% MET: CAR 1:1 and 3:1, 
however, the hardness increased significantly (p< 
0.05) with increased CS content with resultant 
decrease in the swelling capacity (%) and increase in 
the mucoadhesion profile. Table 1 shows that as the 
concentration of MET and CS increased, the 
formulation swelled less due to higher hardness. The 
stickiness (distance travelled before detachment from 
the model mucosa surface) of 2.5% w/v MET: CAR 1:1 
and 3:1 formulations were significantly different with 
a value of 2.31 mm and 1.40 mm respectively, showing 
that increased concentration of MET decreased the 
stickiness (cohesiveness) of the formulations (Figure 
1). For the 4.0% CAR: CS 1:1  and 3:1, the stickiness 
slightly increased from  0.76 mm to 0.86 mm 
respectively, with increased CS. SEM showed a 
porous internal morphology as a result of ice 
nucleation formed during freeze-drying and XRD 
showed that the drug loaded xerogels were crystalline 
in nature due to aspirin. Based on these results, the 
formulations from Table 1, can be tested further for 
drug release to find the optimised xerogel for buccal 
and oral GIT delivery systems respectively. 
 
Fig. 1. Mucoadhesion of aspirin loaded xerogels in human 
saliva. 
 
Table 1. Physicomechanical characteristics of aspirin (ASA) loaded xerogels 
Formulations Hardness (N) Porosity (%) Swelling capacity 
(%) SS 
Swelling capacity 
(%) PBS 
2.5% MET: CAR 3:1 75 mg ASA 5.19 ± 0.03 82 ± 12 302 ± 52 313 ± 21 
2.5% MET: CAR 1:1 75 mg ASA 1.58 ± 0.14 71 ± 2 527 ± 69 540 ± 40 
4.0% MET: CS 1:3 75 mg ASA 2.62 ± 1.08 75 ± 7 179 ± 35 201 ± 37 
4.0% CAR: CS 1:3 75 mg ASA 4.46 ± 0.47 58 ± 7 134 ± 11 154 ± 10 
4.0% CAR: CS 1:1 75 mg ASA 1.10 ± 0.10 69 ± 9 164 ± 10 215 ± 23 
CONCLUSIONS 
Lyophilised 2.5% w/v MET: CAR 1:1 and 3:1, 4.0% 
w/v CAR: CS 1:1 and 3:1 as well as 4.0% MET: CS 1:3 
seems to be very promising systems for the 
administration of low dose aspirin for older patients 
with dysphagia and other age-related problems. 
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